Streetbeat News

Regulatory

RDY

The FDA has completed a product-specific pre-approval inspection at Dr. Reddy's Laboratories' biologics manufacturing facility. The inspection, which took place from October 4-12, resulted in the issuance of a Form 483 with 9 observations.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 1:24 pm

VCYT

Veracyte, Inc. (NASDAQ:VCYT) announced new data demonstrating the clinical utility of its Envisia Genomic Classifier for diagnosing interstitial lung diseases (ILDs). The studies presented at the American College of Chest Physicians (CHEST) Annual Meeting 2023 showed that adding the Envisia Genomic Classifier to the diagnostic process can improve the ability to detect usual interstitial pneumonia (UIP), a condition associated with ILDs that are more likely to progress over time.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 1:17 pm

LEXX

Lexaria has been granted two new patents in Canada, bringing its total to 37 worldwide. The patents cover innovations in delivering lipophilic active drugs and molecules in a water-based format, and infusing tobacco leaves directly with drugs or active molecules for potential applications such as treating nicotine addiction.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 1:15 pm

GEHC

GE HealthCare (NASDAQ:GEHC) has signed a $44 million contract with the Biomedical Advanced Research and Development Authority (BARDA) to develop and obtain regulatory clearance for advanced point-of-care ultrasound technology with new artificial intelligence (AI) applications. The technology will aid in diagnosing lung pathology and traumatic injury, which could be particularly useful in mass casualty situations. The project is supported by federal funds from the Department of Health and Human Services.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 1:11 pm

REVB

Revelation Biosciences Inc. (NASDAQ:REVB) announced that its Gemini formulation showed therapeutic potential in preclinical studies, including as a preventative therapy for infection and acute kidney injury. The company plans to initiate a Phase 1 study later this year and publish the full results of these nonclinical studies. The CEO of Revelation expressed optimism about demonstrating a comparable response in healthy human volunteers.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 1:11 pm

ANGH

Anghami received a written notification from Nasdaq on October 05, indicating that the company is currently not in compliance with Nasdaq Rule 5450(A)(1).

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 1:08 pm

OPTT

Ocean Power Technologies Inc (OPTT) has announced that it will disregard any attempts by Paragon to nominate persons for election to OPTT's board at the company's 2023 Annual Stockholders Meeting.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 1:07 pm

OPTT

Ocean Power Technologies Inc (OPTT) has sent a letter to Paragon Technologies, stating that Paragon failed to submit proper, timely advance notice of nominations in accordance with OPTT's bylaws.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 1:07 pm

MORF

Morphic Holding Inc has reported preliminary cash, cash equivalents, and marketable securities totaling about $725M as of September 30, according to an SEC 8K filing.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 1:00 pm

SHOT

A new study has demonstrated that Safety Shot (SHOT) significantly reduced blood alcohol levels within 30 minutes compared to a control group. A larger double-blinded placebo controlled trial has been initiated.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 12:51 pm